STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report
STAT
JANUARY 31, 2024
and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address. ” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. “Are we at the right balance?
Let's personalize your content